Compare BridgeBio Pharma Inc (BBIO) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs JPMorgan Chase & Co — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while JPMorgan Chase & Co trades at $343.66 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 55.4× BridgeBio Pharma Inc's market cap, and JPMorgan Chase & Co pays a 1.75% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | JPM | |
|---|---|---|
Market Cap | $16.46B | $911.47B |
Sector | Health | Financials |
52-Week High | $90.17 | $342.89 |
52-Week Low | $44.81 | $282.84 |
Enterprise Value | $18.02B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
JPMorgan Chase (JPM) trades at $334.53, down 0.58% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with $181.85B revenue in 2025 and net income of $57.05B, though recent earnings were mixed with a Q4 2025 miss but Q1 and Q2 2026 beats. Analyst consensus is moderately bullish with a $369.67 price target. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings as key catalysts.
JPMorgan presents a solid investment case with robust profitability (31.61% net margin, 17.03% ROE) and reasonable valuation (P/E 14.69). Risks include geopolitical tensions impacting banking operations and cybersecurity threats from advanced AI. The stock offers upside to analyst targets but faces headwinds from economic uncertainty and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
